Ophthalmic Disease Therapeutics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The ophthalmic disease therapeutics market size was valued at USD 35.75 Billion in 2024, driven by the rising number of disorders associated with eyes across the globe. The market size is anticipated to grow at a CAGR of 6.40% during the forecast period of 2025-2034 to achieve a value of USD 66.48 Billion by 2034.
Ophthalmic Diseases: Introduction
Diseases or disorders that infect or impact the eye health in humans are known as ophthalmic diseases. With ever-changing lifestyle changes it is very common to suffer from ophthalmic diseases in today’s time. These disorders may also be the result of some other diseases such as diabetes. The ophthalmic disorder that occurs in diabetic patients is known as diabetic retinopathy (DR).
Ophthalmic Disease Therapeutics Market Analysis
The continuous integration of advanced technologies to predict the treatment demand for ophthalmic diseases is among the major trends propelling the market growth. The rise in ophthalmic disorders or diseases in diabetic patients is also driving market growth. The market has also been witnessing continuous growth as research and development activities associated with the discovery of new drugs or treatments for ophthalmic diseases are on the rise. For example, the drug analysis of an experimental drug 32-134D at Wilmer Eye Institute, Johns Hopkins Medicine was proven to be effective in reducing HIF levels in diseased eyes. This drug analysis was proven effective against slow vision loss in diabetic patients. Eye conditions leading to vision loss are common complications of diabetes and about 8 million Americans are impacted by them. According to the National Institutes of Health, these numbers are expected to nearly double by 2040.
The ophthalmic disease therapeutics market growth is also influenced by the increasing number of clinical trials such as targeted retinal photocoagulation TRP has been proven effective against diabetic retinopathy (DR) and may become a substitute for Pan Retinal Photocoagulation (PRP) in the coming years. The combinational therapy produced out of TRP with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs can also be a potential new approach to expand the treatment regimen for the treatment of diabetic retinopathy. This combinational therapy has been effective on other retinal vascular diseases. The increasing awareness about combinational therapies among people and eye care professionals is also expected to drive market growth.
Ophthalmic Disease Therapeutics Market Segmentations
"Ophthalmic Disease Therapeutics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
The market has been witnessing significant growth due to the increasing geriatric population worldwide. This is due to the development of age-related macular degeneration (AMD) in which the macula is impacted causing central vision loss. The increasing demand for treatment of such eye disorders for the aged population is continuously driving the market growth. The increasing prevalence of chronic diseases such as diabetes is also driving the market growth as it can also cause diabetic retinopathy. The key players in the market are targeting more towards the development of new and improved treatments and drugs.
The increasing research and development activities to develop advanced drugs for the treatment of ophthalmic disorders that may cause total blindness, in the long run, are continuously driving the ophthalmic disease therapeutics market growth. The early diagnosis and timely management of eye conditions such as diabetic retinopathy have been proven effective however, a lack of awareness about the treatments and diagnostic measures for ophthalmic diseases is anticipated to restrict the market growth. According to WHO, refractive errors and cataracts are the leading cause of vision impairment and blindness.
Geographically, North America is leading the global market and is expected to lead throughout the forecast period. The presence of a geriatric population and diabetic patient pool is majorly contributing to the ophthalmic disease therapeutics market share. Eye diseases such as age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma are the leading causes of blindness and low vision in the United States. Diabetic retinopathy (DR) is a common complication of diabetes. It is the leading cause of blindness in American adults.
Ophthalmic Disease Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Ophthalmic Diseases: Introduction
Diseases or disorders that infect or impact the eye health in humans are known as ophthalmic diseases. With ever-changing lifestyle changes it is very common to suffer from ophthalmic diseases in today’s time. These disorders may also be the result of some other diseases such as diabetes. The ophthalmic disorder that occurs in diabetic patients is known as diabetic retinopathy (DR).
Ophthalmic Disease Therapeutics Market Analysis
The continuous integration of advanced technologies to predict the treatment demand for ophthalmic diseases is among the major trends propelling the market growth. The rise in ophthalmic disorders or diseases in diabetic patients is also driving market growth. The market has also been witnessing continuous growth as research and development activities associated with the discovery of new drugs or treatments for ophthalmic diseases are on the rise. For example, the drug analysis of an experimental drug 32-134D at Wilmer Eye Institute, Johns Hopkins Medicine was proven to be effective in reducing HIF levels in diseased eyes. This drug analysis was proven effective against slow vision loss in diabetic patients. Eye conditions leading to vision loss are common complications of diabetes and about 8 million Americans are impacted by them. According to the National Institutes of Health, these numbers are expected to nearly double by 2040.
The ophthalmic disease therapeutics market growth is also influenced by the increasing number of clinical trials such as targeted retinal photocoagulation TRP has been proven effective against diabetic retinopathy (DR) and may become a substitute for Pan Retinal Photocoagulation (PRP) in the coming years. The combinational therapy produced out of TRP with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs can also be a potential new approach to expand the treatment regimen for the treatment of diabetic retinopathy. This combinational therapy has been effective on other retinal vascular diseases. The increasing awareness about combinational therapies among people and eye care professionals is also expected to drive market growth.
Ophthalmic Disease Therapeutics Market Segmentations
"Ophthalmic Disease Therapeutics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Glaucoma
- Dry Eye Diseases
- Retinal Diseases
- Allergy & infections
- Diabetic Retinopathy
- Others
- Anti-inflammatory Drugs
- Anti-infective Drugs
- Anti-VEGF (Vascular Endothelial Growth Factor) Drugs
- Anti-glaucoma Drugs
- Corticosteroids
- Others
- Topical
- Oral
- Intravenous
- Solid
- Liquid
- Semi- Solid
- Hospitals Pharmacies
- Retail pharmacies
- Online Pharmacies
- Others
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
- United States
- EU-4 and the United Kingdom
- Japan
The market has been witnessing significant growth due to the increasing geriatric population worldwide. This is due to the development of age-related macular degeneration (AMD) in which the macula is impacted causing central vision loss. The increasing demand for treatment of such eye disorders for the aged population is continuously driving the market growth. The increasing prevalence of chronic diseases such as diabetes is also driving the market growth as it can also cause diabetic retinopathy. The key players in the market are targeting more towards the development of new and improved treatments and drugs.
The increasing research and development activities to develop advanced drugs for the treatment of ophthalmic disorders that may cause total blindness, in the long run, are continuously driving the ophthalmic disease therapeutics market growth. The early diagnosis and timely management of eye conditions such as diabetic retinopathy have been proven effective however, a lack of awareness about the treatments and diagnostic measures for ophthalmic diseases is anticipated to restrict the market growth. According to WHO, refractive errors and cataracts are the leading cause of vision impairment and blindness.
Geographically, North America is leading the global market and is expected to lead throughout the forecast period. The presence of a geriatric population and diabetic patient pool is majorly contributing to the ophthalmic disease therapeutics market share. Eye diseases such as age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma are the leading causes of blindness and low vision in the United States. Diabetic retinopathy (DR) is a common complication of diabetes. It is the leading cause of blindness in American adults.
Ophthalmic Disease Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Alcon
- Novartis AG
- Bausch Health Companies Inc.
- Merck & Co., Inc.
- Regeneron Pharmaceuticals Inc
- Allergan
- Bayer AG
- Genentech, Inc.
- Nicox
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Ophthalmic Disease Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Ophthalmic Disease Epidemiology Analysis-7MM
- 5.1 Epidemiology Overview (2018-2034)
- 5.2 United States Ophthalmic Disease Epidemiology (2018-2034)
- 5.3 EU-4 and United Kingdom Ophthalmic Disease Epidemiology (2018-2034)
- 5.4 Japan Ophthalmic Disease Epidemiology (2018-2034)
- 6 Ophthalmic Disease Therapeutics Market Overview
- 6.1 Ophthalmic Disease Therapeutics Market Historical Value (2018-2024)
- 6.2 Ophthalmic Disease Therapeutics Market Forecast Value (2025-2034)
- 7 Ophthalmic Disease Therapeutics Market Landscape
- 7.1 Ophthalmic Disease Therapeutics Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Ophthalmic Disease Therapeutics Product Landscape
- 7.2.1 Analysis by Disease Type
- 7.2.2 Analysis by Drug Class
- 7.2.3 Analysis by Route of Administration
- 8 Ophthalmic Disease Treatment Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Ophthalmic Disease Therapeutics Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Ophthalmic Disease Therapeutics Market Segmentation
- 11.1 Ophthalmic Disease Therapeutics Market by Disease Type
- 11.1.1 Market Overview
- 11.1.2 Glaucoma
- 11.1.3 Dry Eye Disease
- 11.1.4 Retinal Disease
- 11.1.5 Allergy and Infections
- 11.1.6 Diabetic Retinopathy
- 11.1.7 Others
- 11.2 Ophthalmic Disease Therapeutics Market by Drug Class
- 11.2.1 Market Overview
- 11.2.2 Anti-inflammatory Drugs
- 11.2.3 Anti-infective Drugs
- 11.2.4 Anti-VEGF (Vascular Endothelial Growth Factor) Drugs
- 11.2.5 Anti-glaucoma Drugs
- 11.2.6 Corticosteroids
- 11.2.7 Others
- 11.3 Ophthalmic Disease Therapeutics Market by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Topical
- 11.3.3 Oral
- 11.3.4 Intravenous
- 11.4 Ophthalmic Disease Therapeutics Market by Dosages Form
- 11.4.1 Market Overview
- 11.4.2 Solid
- 11.4.3 Liquid
- 11.4.4 Semi- Solid
- 11.5 Ophthalmic Disease Therapeutics Market by Distribution Channel
- 11.5.1 Market Overview
- 11.5.2 Hospitals Pharmacies
- 11.5.3 Retail pharmacies
- 11.5.4 Online Pharmacies
- 11.5.5 Others
- 11.6 Ophthalmic Disease Therapeutics Market by End User
- 11.6.1 Market Overview
- 11.6.2 Hospitals
- 11.6.3 Clinics
- 11.6.4 Ambulatory Surgical Centers
- 11.6.5 Homecare Settings
- 11.6.6 Others
- 11.7 Ophthalmic Disease Therapeutics Market by Region-7MM
- 11.7.1 Market Overview
- 11.7.2 United States
- 11.7.3 EU-4 and the United Kingdom
- 11.7.4 Japan
- 12 United States Ophthalmic Disease Therapeutics Market
- 12.1 U.S. Ophthalmic Disease Therapeutics Market Historical Size (2018-2024)
- 12.2 U.S. Ophthalmic Disease Therapeutics Market Forecast Size (2025-2034)
- 12.3 Market Size by Drug Class
- 13 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market
- 13.1 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market Historical Size (2018-2024)
- 13.2 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market Forecast Size (2025-2034)
- 13.3 Market Size by Drug Class
- 14 Japan Ophthalmic Disease Therapeutics Market
- 14.1 Japan Ophthalmic Disease Therapeutics Market Historical Size (2018-2024)
- 14.2 Japan Ophthalmic Disease Therapeutics Market Forecast Size (2025-2034)
- 14.3 Market Size by Drug Class
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Pfizer Inc.
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisition
- 21.1.5 Certifications
- 21.2 Alcon
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisition
- 21.2.5 Certifications
- 21.3 Novartis AG
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisition
- 21.3.5 Certifications
- 21.4 Bausch Health Companies Inc.
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisition
- 21.4.5 Certifications
- 21.5 Merck & Co., Inc.
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisition
- 21.5.5 Certifications
- 21.6 Regeneron Pharmaceuticals Inc
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisition
- 21.6.5 Certifications
- 21.7 Allergan
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisition
- 21.7.5 Certifications
- 21.8 Bayer AG
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisition
- 21.8.5 Certifications
- 21.9 Genentech, Inc.
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisition
- 21.9.5 Certifications
- 21.10 Nicox
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisition
- 21.10.5 Certifications
- 22 Ophthalmic Disease Therapeutics Market - Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
